$1.39
3.47% yesterday
Nasdaq, Sep 23, 10:14 pm CET
ISIN
US46333X1081
Symbol
IRWD

Ironwood Pharmaceuticals Stock price

$1.39
+0.12 9.45% 1M
-0.10 6.71% 6M
-3.04 68.62% YTD
-2.69 65.93% 1Y
-8.79 86.35% 3Y
-8.08 85.32% 5Y
-7.77 84.82% 10Y
-8.36 85.75% 20Y
Nasdaq, Closing price Tue, Sep 23 2025
-0.05 3.47%

Key metrics

Basic
Market capitalization
$225.8m
Enterprise Value
$717.3m
Net debt
$491.5m
Cash
$92.9m
Shares outstanding
162.4m
Valuation (TTM | estimate)
P/E
negative | 6.5
P/S
0.7 | 0.8
EV/Sales
2.3 | 2.6
EV/FCF
24.0
P/B
negative
Financial Health
Equity Ratio
-85.9%
Return on Equity
-0.3%
ROCE
83.0%
ROIC
-6.8%
Debt/Equity
-1.9
Financials (TTM | estimate)
Revenue
$308.5m | $279.8m
EBITDA
$93.6m | $104.0m
EBIT
$91.6m | $81.5m
Net Income
$-7.9m | $34.8m
Free Cash Flow
$29.9m
Growth (TTM | estimate)
Revenue
-23.0% | -20.4%
EBITDA
-27.2% | 6.5%
EBIT
-27.5% | -14.9%
Net Income
-185.7% | 3,853.4%
Free Cash Flow
-75.0%
Margin (TTM | estimate)
Gross
-
EBITDA
30.3% | 37.2%
EBIT
29.7%
Net
-2.6% | 12.4%
Free Cash Flow
9.7%
More
EPS
$-0.1
FCF per Share
$0.2
Short interest
5.7%
Employees
253
Rev per Employee
$1.4m
Show more

Is Ironwood Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Ironwood Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Ironwood Pharmaceuticals forecast:

7x Hold
70%
3x Sell
30%

Analyst Opinions

10 Analysts have issued a Ironwood Pharmaceuticals forecast:

Hold
70%
Sell
30%

Financial data from Ironwood Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
309 309
23% 23%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 111 111
26% 26%
36%
- Research and Development Expense 106 106
15% 15%
34%
94 94
27% 27%
30%
- Depreciation and Amortization 1.94 1.94
5% 5%
1%
EBIT (Operating Income) EBIT 92 92
28% 28%
30%
Net Profit -7.89 -7.89
186% 186%
-3%

In millions USD.

Don't miss a Thing! We will send you all news about Ironwood Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ironwood Pharmaceuticals Stock News

Positive
The Motley Fool
about 2 months ago
Ironwood (IRWD) Q2 EPS Jumps 600%
Neutral
Business Wire
about 2 months ago
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its second quarter 2025 results and recent business performance. “In the second quarter, LINZESS delivered $248 million in U.S. net sales with robust EUTRx demand grow...
Neutral
Business Wire
5 months ago
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its first quarter 2025 results and recent business performance. “LINZESS demand continues to be strong, and we remain on track to meet our full-year 2025 guidance and ...
More Ironwood Pharmaceuticals News

Company Profile

Ironwood Pharmaceuticals, Inc. is a commercial biotechnology company, which engages in the discovery, commercialization, and development of medicines. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.

Head office United States
CEO Thomas McCourt
Employees 253
Founded 1998
Website www.ironwoodpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today